Daniel Omstead was named senior vice president of researchand development at CytoTherapeutics Inc. of Providence, R.I.He was senior director of bioprocess development at R.W.Johnson Pharmaceutical Research Institute, a division ofJohnson & Johnson.
Aastrom Biosciences of Ann Arbor, Mich., has named LyndaDreiling vice president and chief financial officer. She waspreviously chief operating officer, executive vice president,chief financial officer and secretary treasurer at Staodyn Inc.
Jack Bowman, retiring company group chairman of Johnson &Johnson, and Robert Swanson, chairman of the board ofGenentech Inc., have been appointed to the newly createdbusiness advisory board of Geron Inc. of Menlo Park, Calif.
Vertex Pharmaceuticals Inc. of Cambridge, Mass., has added toits board of directors Donald Conklin, president of Schering-Plough Pharmaceuticals, and Barry Bloom, retired executivevice president for research and development at Pfizer Inc.
Bloom was also recently appointed to the board of NeurogenCorp. The Branford, Conn., company also appointed MarkNovitch, formerly in charge of regulatory affairs, qualitycontrol, legal, public, government affairs and strategic planningat Upjohn Co. Prior to joining Upjohn, Novitch was a top FDAofficial.
Celtrix Pharmaceuticals Inc. of Santa Clara, Calif., has namedDavid Rosen director of research. He was previously programdirector for the company's osteoporosis project.
Paul Baehr, formerly executive vice president of SterlingWinthrop's Pharmaceutical Group, has been appointed vicechairman and chief executive officer of Ibex Technologies Inc.of Montreal. The Canadian company's founder, Robert Heft, willremain president.
(c) 1997 American Health Consultants. All rights reserved.